We investigated the in vitro hematopoietic stimulatory activity of leukemia inhibitory factodhuman interleukin for DA cells (LIF/HILDA) on bone marrow progenitor populations in 17 normal individuals. In serum-free cultures LIF/HILDA did not induce colony growth. In serum containing media, LIF/ HILDA stimulated the growth of colony forming unit (CFUj-MIX and CFU-EO in a dose-dependent fashion and resulted in an increased CFU-MIX and burst forming unit-erythrocytes (BFU-E) colony size. Similar stimulatory effects were seen on a highly purified hematopoietic progenitor population obtained after immunomagnetic depletion of mature myeloid precursors and lymphoid cells. Addition of LIF/HILDA to cultures containing maximally stimulatory concentrations of recombinant human interleukin-3 (rhulLB), rhulL3 + rhulL6, or rhu granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) in serum containing media significantly increased the number of CFU-MIX and eosinophil colonies and ROLIFERATION and differentiation of human he-P matopoietic progenitor cells is dependent on specific combinations of hematopoietic growth factors. Although the factors that regulate self-renewal and differentiation in the earliest stages of stem-cell development are not well known, different classes of hematopoietic growth factors exist that stimulate either multi-lineage or single-lineage progenitor cells. Hematopoietic growth factors affecting progenitors of several lineages as well as more primitive multipotential progenitor cells include granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3).'.' Growth factors which have synergistic effects with either IL-3 or GM-CSF for the generation of muitilineage colonies include IL-l,3 IL-6; and G-CSF? These growth factors lack the ability to stimulate multi-lineage colony growth when used as the sole CSF.
Recently, cDNA for a novel human hematopoietic growth factor termed leukemia inhibitory factor (LIF) or human interleukin for DA cells (HILDA) has been isolated."' LIF/HILDA has a broad spectrum of biologic activities including in vitro suppression of terminal differentiation of mouse embryonic stem cell^,^.^ differentiating effects on peripheral and central neurons," in vitro differentiating effects on some malignant hematopoietic cell and proliferative effects on other^.^," In vivo, LIF/HILDA induces cachexia, pancreatitis,16 and oste~sclerosis'~~'' combined with increased splenic hematopoiesi~.'~ When present in high concentrations LIF/HILDA causes leukocytosis and an increase in number of immature blasts present in hematopoietic 0rgar1s.l~ Several studies examined the in vitro effects of LIF/ HILDA on normal murine and human bone marrow progenitors. LIF/HILDA does not influence the growth of relatively mature colony-forming unit (CFU)-GM progenitor^'^.'^.'^ but displays burst-promoting activity for human bone marrow progenitors when used in combination with erythropoietin." It has been shown that this lymphokine has strong chemotactic and activating properties on increased size and cluster number of CFU-MIX and BFU-E. Depletion of accessory T lymphocytes or monocytes from bone marrow progenitors did not alter the response of hematopoietic precursors to LIF/HILDA. A similar increased colony growth was seen when LIF/HILDA was added to cultures of positively selected CD34+/HLA-DR+ or CD34+/HLA-DR-bone marrow hematopoietic progenitor cells stimulated with maximally stimulatory concentrations of rhulL3 + rhulL6.
LIF/HILDA is a novel cytokine capable of stimulating growth and proliferation of multi-lineage, erythroid, and eosinophil colonies in the presence of serum. LIF/HILDA exerts its activity by direct interaction with highly purified immature bone marrow progenitor cells, has an additive effect when used with other cytokines known to stimulate primitive hematopoietic precursors, and does not require accessory cells.
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mature eosinophils both in mice and human^.'*^'^ LIF/ HILDA may induce proliferation without restriction of the developmental potential of immature CFU-S in mice," and augment the IL-3-dependent proliferation of early human hematopoietic blast cell colony progenitor cells?' Although the receptor for LIF/HILDA is unknown, murine IzI-LIF binding studies show that LIFMILDA binds specifically to myeloid leukemia cell lines, and to cells of different murine hematopoietic tissues including bone marrow and spleen.18 mRNA for LIF/HILDA has been found in cultured heart myoblasts," lectin-stimulated peripheral blood T lymphocytes,' monocytes,18 and human bone marrow stromal cells,'' indicating a possible role for LIF in human hematopoietic differentiation and proliferation.
In this report we investigate the effect of LIF/HILDA on normal human hematopoietic progenitor cells. We show that LIF/HILDA is a hematopoietic growth factor capable of inducing growth and increased proliferation of immature multi-lineage colonies in serum-containing cultures. We also show that LIFMILDA exerts an additive effect when
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VERFAlLLlE AND McGLAVE used with other multi-lineage growth factors. These effects on progenitor cells occur by direct interaction of LIF/ HILDA with purified progenitor populations and do not require the presence of accessory cells.
MATERIALS AND METHODS

Bone Marrow Populations
Heparinized (Solopak Lab, Franklin Park, 11) bone marrow was obtained by aspiration from the posterior iliac crest of 17 normal adult volunteers. Informed consent was obtained using guidelines approved by the Committee on the Use of Human Subjects at the University of Minnesota in all cases. Bone marrow mononuclear cells (BMMNC) were isolated by Ficoll-Hypaque (Sigma Diagnostics, St Louis, MO) density gradient centrifugation (specific gravity 1.077) for 30 minutes at 3 7 T and 40%.
Monocytes were depleted from BMMNC (BMMNC-MO) by two cycles of 1-hour plastic adherence in Iscoves Modified Dulbec-CO'S medium (IMDM) (GIBCO Laboratories, Grand Island, NY) supplemented with 20% fetal calf serum (FCS) (HycloneLaboratories, Logan, UT) in T25 culture flasks (Corning Glass Works, Corning, NY) at 37°C and 5% CO,. Wright-Giemsa stained cytospin preparations of BMMNC-MO showed less than 2% contaminating monocytes after two cycles of plastic adherence.
T lymphocytes were depleted from BMMNC (BMMNC-T) by rosetting of bone marrow cells with 2-amino ethylisothiouronium bromide (AET)-treated sheep red blood cells (RBC) at 4°C for 1 hour. Nonrosetted cells were separated by a second FicollHypaque density gradient ~edimentation.'~ Fluorescence-activated cell sorter (FACS) analysis of BMMNC-T labeled with anti-CD3 (Leu4) monoclonal antibody (MoAb) (Becton-Dickinson, Mountain View, CA) showed less than 1% contaminating T lymphocytes.
In four cases marrow cells were enriched for primitive hematopoietic progenitors by an immunomagnetic depletion of committed myeloid cells, monocytes, and lymphoid precursors." All preparations were done on ice using cold media to minimize nonspecific binding. BMMNC were incubated for 30 minutes at 4°C with a mixture of 0.5 p8/106 cells MoAbs with overlapping specificity for T and B lymphocytes, natural killer (NK) cells, monocyte and myeloid lineage including anti-CD2 (leu 5), anti-CD3 (leu 4), anti-CD16 (leu ll), anti-CD11 (leu 15), anti-CD15 (MY-18), anti-CD19 (leu 12), antLCD56 (leu 19), and anti-CD71 (transferrin receptor) (Becton-Dickinson). Cells were washed twice and incubated with immunomagnetic beads coated with goat antimouse IgG and IgM (Advanced Magnetics Inc, Cambridge, MA) for 30 minutes at 4°C with periodic agitation (40 x lo6 beads were used per lo6 cells). Rosettes and free particles were removed using a BioMag Separator (Advanced Magnetics Inc). The rosette-free fraction was inspected for the presence of rosettes and, if necessary, the above procedure was repeated once or twice. The rosette-positive fraction was washed twice and the nonrosetted cells were recovered. The rosette-positive fraction was washed twice and the nonrosetted cells were recovered. The rosette-free fraction was called lineage-negative BMMNC (Lin-). To assess the effectiveness of the immunomagnetic depletion, BMMNC and Lin-cells were analyzed for the presence of cells bearing the CD2, CD3, CDllb, CD15, CD16, CD19, CD56, and CD71 antigens. Lincells obtained after immunomagnetic separation were first incu- 
Growth Factors
LIFLHILDA, recombinant human IL-3 (rhuIL-3), and rhuIL-6 were a generous gift from Dr G. Wong (Genetics Institute, Cambridge, MA). LIFLHILDA was obtained as media conditioned by COS cells transfected with the cDNA-pC106P-vector encoding LIF or HILDA. This conditioned media is half maximally active at a final dilution of 1:100,000. Supernatant of mock transfected COS cells, used to control for the specific activity of LIFLHILDA, was obtained from Dr G . Wong. rhuIL-3 and rhuIL-6 were produced in Escherichia coli and have a specific activity of 2.5 x lo6 U/mg (rhuIL-3) and 4 x lo6 U/mg (rhuIL-6), respectively. rhuGM-CSF was obtained from Amgen Biologicals (Thousand Oaks, CA) and has a specific activity of 2 4 x lo7 U/mL. rhu erythropoietin (Epoietin) was obtained from Amgen. Lin-34+DR-cells were suspended in triplicates in 4-well plates (Nunclone, Roskilde, Denmark) in IMDM containing methylcellulose (final concentration 1.12%) (Fisher Scientific, Fair Lawn, NY) supplemented with 30% FCS, 10.' mol/L 2-mercaptoethanol (Sigma), 3 IU recombinant erythropoietin, and various combinations of hematopoietic growth factors as indicated. Cultures were kept at 37°C and 5% CO, in a humidified atmosphere for 14 to 21 days. Cultures were assessed for the presence of burst-forming unit-erythrocytes (BFU-E) and CFU-MIX as previously described.'' CFU-GM and CFU-EO colonies were enumerated according to their morphologic appearance. The nature of the colonies was verified periodically by plucking the colonies from the culture plates with a finely drawn Pasteur pipette and performing cytologic examination of Wright-Giemsa stained cytospin preparations. BMMNC/mL (1 x IO') was suspended in doublets or quadruplets in 35-mm culture dishes (Costar, Cambridge, MA) in alpha-MEM (GIBCO) containing methylcellulose (final concentration 1.12%) supplemented with 3% deionized crystalline bovine serum albumin (BSA) (Sigma), lo-' mol/L 2-mercaptoethanol B, 3 IU erythropoietin, 300 pg/mL transferrin (iron-saturated, purity > 98%; Sigma), 10 pg/mL insulin (Sigma), 10'" mol/L sodium-selenite (Sigma), 6 pg/mL cholesterol (Sigma), and 10 pg/mL L-phosphatidylcholine (Sigma) with or without various concentrations of LIF/HILDA. Cultures were maintained at 37°C. 5% CO, in a humidified atmosphere for 14 to 16 days. Cultures were assessed for the presence of BFU-E, CFU-GM, CFU-EO, and CFU-MIX as described above.
Methylcellulose Cultures
Sentm-free cultures.
Statistics
Results of experimental points obtained from multiple experiments were reported a s the mean 2 1 standard error of the mean (SEM). Significance levels were determined by two-sided Student's r-test analysis. 
RESULTS
We
bars) that reached a maximum of 228% t 12.7% increase at a dilution of 1:200 (P < .001). There was a minimal increase in growth of BFU-E (124% 2 8.5%) (P = .01) (dotted bars), while no change in number of CFU-GM (P = NS) (hatched bars) was detected.
We next examined the effect of LIF/HILDA on BMMNC stimulated with optimal concentrations of various hematopoietic growth factors in serum-containing media. As indicated in Fig 3, there was a dose-dependent increase in number of CFU-MIX colonies (Fig 3A) whcn LIF/HILDA was added to cultures of BMMNC in the presence of maximally stimulatory concentrations of rhuIL-3 (black bars) (n = 9) (232% 2 97% at LIF/HILDA Concentration 1:200 P < .001), a combination of rhuIL-3 + rhuIL-6 (hatched bars) (n = 4) (202% t 25% at LIF concentration 1:200; P = .002), or rhuGM-CSF (dotted bars) (n = 6) (241% 2 67% at LIF/HILDAconcentration 1:2oO;P = .02). Under similar conditions, CFU-EO colonies (Fig 3B) increased in a dose-dependent fashion with the addition of LIF/HILDA to either rhuIL-3 (277% t 47% increase at LIF/HILDA concentration 1:200; P = .002), rhuIL-3 + rhuIL-6 (203% t 35% increase at LIF/HILDA concentration 1:200P = .01), or rGM-CSF (230% 2 29% increase at LIF concentration 1:200; P = .002). Addition of LIF/ HILDA in serum-containing media to other growth factors resulted in an insignificant increase in numbers of BFU-E (Fig 3C) and CFU-GM (Fig 3D) . The growth promoting effects of LIF/HILDA on immature progenitors maximally stimulated with other cytokines seems to be additive (Fig 4 and Table 1 ). Addition of LIF/HILDA (1:200) to cultures maximally stimulated with rhuIL-3 alone resulted in an approximate doubling of CFU-MIX (Fig 4A) and CFU-EO (Fig 48) colony number compared with cultures stimulated with either LIF/HILDA or rhuIL-3 alone. A similar approximate doubling of CFU-MIX and CFU-EO colony number was seen when LIF/HILDA was added to cultures maximally stimulated with rhuIL-3 + rhuIL-6 or rhuGM-CSF.
We performed additional studies (n = 4) in which the effect of LIF/HILDA on bone marrow progenitor cells was compared with the effect of control supernatant from mock transfected COS cells (SN-Mock). As can be seen in Fig 5, For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From We next examined the role of accessory cells in the observed growth and proliferation promoting activity of LIFMILDA. Depletion of monocytes (widely hatched bars), T lymphocytes (dotted bars), or monocytes plus T lymphocytes (open bars) from BMMNC did not alter the response of bone marrow progenitor cells to LIFMILDA in combination with rhuIL-3 (2 ng/mL) (Fig 6) . The 232% 68% increase in CFU-MIX at an LIFMILDA concentration of 1:200 for BMMNC (black bars) (n = 9) was comparable with the 257% f 72% increase for BMMNC-MO (n = 7) ( P = NS), the 172% 2 32% increase for BMMNC-T (n = 7) (P = NS), and the 369% f 69% increase for BMMNC-MO-T (n = 7) (P = NS) (Fig 6A) . Likewise, increase in CFU-EO colony growth (Fig 6B) was similar when different bone marrow subpopulations were cultured with rhuIL-3 and increasing concentrations of LIFMILDA [P = NS]; BMMNC-T: 222% & 6.1% [P = NS]; and BM-MNC-MO-T 237% f 32% [P = NS]). An insignificant increase was shown in BFU-E colony number (Fig 6C) and no effect on CFU-GM growth could be found (Fig 6D) .
We then examined the effect of LIFMILDA on purified bone marrow progenitor cells obtained after negative immunomagnetic depletion of cells bearing antigens of committed myeloid, monocyte, or lymphoid origin (Fig 6, dark (BMMNC 262% f 58%; BMMNC-MO: 211% f 11.1% Table 1 
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IL3+IL6 GM-CSF IL3 IL3+IL6 GM-CSF hatched bars)." The immunomagnetic depletion step resulted in a greater than 95% removal of cells bearing CD2, CD3, CDlla, CD15, CD16, CD19, CD56, or CD71 antigens (n = 4). In four individuals Lin-BMMNC were plated in serum-containing media with rhuIL-3 and increasing concentrations of LIFMILDA. We showed a dose-dependent increase in CFU-MIX (334% f 75%; P = .003) (Fig 6A) and CFU-EO (236% f 28%; P = .004) (Fig 6B) colony number, while an insignificant increase in number of BFU-E colonies ( Fig 6C) and no effect on CFU-GM ( Fig  6D) colony number could be found. Finally, we examined the effect of LIFMILDA (1:1,000 dilution) on FACS-sorted Lin-34'DR+ (hatched bars) or Lin-34+DR-(dotted bars) hematopoietic progenitors stimulated maximally with rhuIL-3 (2 ng/mL) (Fig 7) . We show a significant increase in CFU-MIX colonies (Lin-34'DR': 254% f 54% increase; P = .03; Lin-34+DR-: 243% f 45% increase; P = .02); and CFU-EO colonies (Lin-34+DR+: 182% f 21% increase;P = .008; Lin-34'DR-: 201% 2 19% increase; P = .002) similar to what was seen in cultures of undepleted bone marrow cells (solid bars) (P = NS). These data suggest that LIFMILDA is capable of interacting directly with immature bone marrow hcmatopoietic progenitor cells.
DISCUSSION
This study shows that in the presence of serum LIF/ HILDA alone supports the growth of multipotential CFU-MIX colonies. The stimulation of hematopoietic progenitors is specific for LIFMILDA because addition of control SN-Mock had no such effects on progenitor colony growth. However, when LIF/HILDA was used as the sole growth factor in serum-free cultures, no colony growth was observed indicating that factor(s) in serum are necessary for the manifestation of its growth stimulating activities. Combination of LIFMILDA with rhuGM-CSF or rhuIL-3 in serum-containing media resulted in a significant increase in CFU-MIX colony formation in comparison with rhuGM-CSF, rhuIL-3, or LIF/HILDA alone. These results suggest that LIFMILDA exerts an additive effect with hematopoietic growth factors known to induce growth of multipotential bone marrow progenitor cells. The effects of LIFMILDA on hematopoietic progenitors are similar to growth stimulatory effects previously described for rhuIL-6. rhuIL-6 potentiates the growth-promoting effects of rhuIL-3 or rhuGM-CSF for the generation of multi-lineage and single-lineage c o l o n i e~.~~~~~~~ rhuIL-6 has the potential to induce growth of mixed colonies when used alone under serum-containing conditions but fails to do so when used alone in serum-free media.= We show here that LIF/HILDA exerts additive effects with optimally active concentrations of rhuIL-3 combined with optimally active concentrations of rhuIL-6 for the generation of multi-lineage colonies. These findings suggest that, despite their similarities, LIFBILDA and rhuIL-6 exert independent, additive effects on the growth of human hematopoietic progenitors.
When LIFBILDA was added to bone marrow progenitor cultures either alone or in combination with other growth factors we showed not only an increased number of CFU-MIX colonies but also a significant increase in size of CFU-MIX colonies. Although no significant increase was seen in BFU-E colony number, we observed an increase in size and multicentricity of BFU-E colonies when LIF/ HILDA was added alone or in combination with other growth factors. These findings suggest that LIF/HILDA increases the proliferative capacity of immature multipotent and unipotent bone marrow progenitor cells. Other cytokines such as rhuIL-6,= G-CSF: and a factor(s) in conditioned media from a murine stromal cell line" exert similar additive or synergistic growth-promoting activity for multi-potential precursors when added to cultures containing IL-3, GM-CSF, and CSF-1, and increase both size and number of colonies. As for G-CSF and IG6, mRNA for LIFMILDA has been detected in human bone marrowderived stromal fibroblast cells.22 A rapid increase in serum levels of all three cytokines has been observed after injection of endotoxin in mice.14 LIF/HILDA, G-CSF, and IL-6 share the capacity of independently inducing differentiation in mice myeloid leukemic cell line~.6-"-'~ Our observation that both LIF/HILDA and IL-6 are capable of supporting growth and proliferation of immature multiand single-lineage bone marrow progenitor cells in an independent but additive fashion suggests an additional similarity in the biologic actions of IL-6 and LIFBILDA.
Receptors for LIF/HILDA have been demonstrated on murine monocytes and macrophages." The possibility exists that LIF/HILDA exerts its activity through accessory monoFor personal use only. on August 16, 2017 . by guest www.bloodjournal.org From cytes. Because depletion of monocytes from BMMNC by plastic adherence or immunomagnetic depletion with a combination of MoAbs including anti-CD1 1 and anti-CD15 did not affect the observed growth-promoting activity of LIF/HILDA, it seems unlikely that LIF/HILDA exerts its activity indirectly through induction of cytokine production in bone marrow monocytes. The growth-promoting activity of LIF/HILDA was also not dependent on the presence of T lymphocytes. The increase in growth of CFU-MIX colonies and the increased size of CFU-MIX and BFU-E colonies seen in cultures of purified hematopoietic progenitors obtained after either negative immunomagnetic dcpletion of committed myeloid or lymphoid progenitors or positive FACS sorting for cells expressing CD34 antigens supports the hypothesis that LIF/HILDA can interact directly with immature hematopoietic progenitor cells. In accordance with previous reports,'2~'p~" we were unable to demonstrate proliferative effects on relatively mature CFU-GM by addition of LIF/HILDA either alone or in combination with other growth factors. However, we demonstrate a significant increase in number of eosinophil colonies independent of the presence of accessory cells when LIF/HILDA is added to serum-containing culture systems. This finding is in contrast with previous reports'' that failed to demonstrate an effect of LIF/HILDA on both proliferation and differentiation of immature eosinophil progenitors. Because we show that factor(s) present in serum are necessary for the manifestation of the growthFor personal use only. on August 16, 2017 . by guest www.bloodjournal.org From promoting and proliferative potential of LIF/HILDA for eosinophil precursors, the higher concentration of FCS (30%) used in our culture system compared with what has been reported (lo%)'* may underlie the discrepancies between our results and previous reported experiments. LIF/HILDA was initially purified from T-cell clones derived from lymphocytes infiltrating irreversibly rejected renal allografts.' Blood eosinophilia which is most likely induced by cytokines derived from alloreactive T lymphocytes has been observed early in the course of a rejection crisis.28 Therefore, LIF/HILDA may be one of the cytokines responsible for the induction of peripheral blood eosinophilia associated with acute renal allograft rejection.
In conclusion, we demonstrate that LIF/HILDA is a growth factor for immature multilineage progenitor cells that requires factor(s) present in serum for the manifestation of its activity. LIF/HILDA exerts an additive effect on colony growth and proliferation with rhuGM-CSF, rhuIL-3, and a combination of rhuIL-3 + rhuIL-6 by direct interaction with its target cells independent of accessory cell populations. LIF/HILDA also has growth-promoting potential for eosinophil precursor cells.
